• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TYMS Gene Record

  • Summary
  • Interactions
  • Claims
  • TYMS 7298 Druggable GenomeDrug Resistance

    Alternate Names:

    7298
    THYMIDYLATE SYNTHETASE
    TYMS
    HST422
    TMS
    TS
    188350
    12441
    ENSG00000176890
    OTTHUMG00000131473
    Thymidylate synthase
    TSase
    PA359
    TYSY_HUMAN
    P04818
    5971
    THYMIDYLATE SYNTHASE (EC 2.1.1.45) (TS) (TSASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04818]
    T98397

    Gene Info:

    Target Main Class Enzymes
    Target Subclass 2.1.1.45
    Human Readable Name DRUGGABLE GENOME
    Target Class Enzymes
    Target Subclass EC:2.1.1.45
    Interpro Short Name Thymidylate_synthase
    Interpro Name Thymidylate synthase
    Uniprot Status Swiss-Prot
    Interpro Acc IPR000398
    Interpro Type Family
    Uniprot Evidence 1: Evidence at protein level
    Gene Biotype PROTEIN_CODING
    (12 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    DRUGGABLE GENOME
    ENZYME

    Publications:

    Fischel et al., 2006, Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine., Anticancer Drugs
    Carlini et al., 2005, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan., Clin. Cancer Res.
    Li et al., 2005, Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Patel et al., 2004, Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults., Cancer Chemother. Pharmacol.
    Eliason et al., 2004, Potential for predicting toxicity and response of fluoropyrimidines in patients., Curr Drug Targets
    Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood
    Inoue K et al., 2014, Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy., Drug Metab Pharmacokinet
    Freyer G et al., 2011, Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study., Anticancer Res
    Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer
    Martinez-Balibrea et al., 2010, UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy., Br. J. Cancer
    Tsukamoto et al., 1989, Effect of glucocorticoid on liver regeneration after partial hepatectomy in the rat., Gut
    Pelà M et al., 2014, Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth., J Med Chem
    Huang et al., 2006, Tailor-made chemotherapy for non-small cell lung cancer patients., Future Oncol
    Garcia et al., 2006, Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential., Clin. Cancer Res.
    Fernández-Contreras et al., 2006, Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil., Int. J. Oncol.
    Formentini et al., 2007, Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?, Int J Colorectal Dis
    Ploylearmsaeng et al., 2006, How may anticancer chemotherapy with fluorouracil be individualised?, Clin Pharmacokinet
    Rustum, 2004, Thymidylate synthase: a critical target in cancer therapy?, Front. Biosci.
    Singh V et al., 2015, The complex mechanism of antimycobacterial action of 5-fluorouracil., Chem Biol
    Chen et al., 2011, Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed., Lung Cancer
    Kasai et al., 2013, Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma., Anticancer Res.
    Shimizu et al., 2012, Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer., Anticancer Res.
    Chamizo et al., 2015, Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer., BMC Pulm Med
    Pivot et al., 2001, Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck., Br. J. Cancer
    Kindler, 2002, Pemetrexed in pancreatic cancer., Semin. Oncol.
    Hanauske et al., 2001, Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors., Oncologist
    Adjei, 2001, Gemcitabine and Pemetrexed disodium in treating breast cancer., Oncology (Williston Park, N.Y.)
    Adjei, 2002, Pemetrexed in the treatment of selected solid tumors., Semin. Oncol.
    Giovannetti et al., 2005, Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells., Mol. Pharmacol.
    Norman, 2001, Pemetrexed disodium (Eli Lilly)., Curr Opin Investig Drugs
    Schultz et al., Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells., Anticancer Res.
    Molina et al., 2003, The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy., Clin Lung Cancer
    Adjei, 2001, Gemcitabine and pemetrexed disodium combinations in vitro and in vivo., Lung Cancer
    Cao et al., 1999, Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine., Clin. Cancer Res.
    Orlandi et al., 1999, Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex., Br. J. Cancer
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Chen et al., 1999, Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells., Semin. Oncol.
    Ferguson et al., 1999, Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells., Br. J. Pharmacol.
    Yang et al., 2008, DNA damage and homologous recombination signaling induced by thymidylate deprivation., Biochem. Pharmacol.
    Grem et al., 1999, A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors., Clin. Cancer Res.
    Yin et al., 1999, Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex., Exp. Cell Res.
    Salgado J et al., 2007, Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer., Oncol Rep
    Suzuki et al., Effects of tamoxifen on mammary tumors and bone in 7,12-dimethylbenz-(a)anthracene-treated rats., Anticancer Res.
    Barbour et al., 1988, Glucocorticoid regulation of the genes encoding thymidine kinase, thymidylate synthase, and ornithine decarboxylase in P1798 cells., Mol. Endocrinol.
    James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol
    FitzGerald et al., 1987, Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine., Anticancer Drug Des.
    Newman et al., 1988, Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin., Biochem. Pharmacol.
    Goldstein S et al., 1984, Interaction of N4-hydroxy-2'-deoxycytidylic acid with thymidylate synthetase., J Med Chem
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Lee MN et al., 2015, Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine., Inflamm Bowel Dis
    Kubota, 1999, [Theoretical basis for low-dose CDDP/5-FU therapy]., Gan To Kagaku Ryoho
    Murakami et al., 2000, Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells., Int. J. Oncol.
    Kuwa et al., Effects of a low dose leucovorin with 5-fluorouracil derivative on colorectal tumors induced with 1,2-dimethylhydrazine in rats., Anticancer Res.
    Kuwa et al., Effects of long-term administration of UFT plus leucovorin on colorectal tumors induced with 1,2-dimethylhydrazine in rats., Anticancer Res.
    Voeller et al., 2000, Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs., Cancer Chemother. Pharmacol.
    Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
    Berne et al., 1988, Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat., Cancer Invest.
    Nakata et al., 1985, Alpha-adrenergic regulation of the activity of thymidylate synthetase and thymidine kinase during liver regeneration after partial hepatectomy., Eur. J. Pharmacol.
    Visani G et al., 2018, MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine., Pharmacogenomics J
    Cao et al., 2000, alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil., Biochem. Pharmacol.
    Kamm et al., 2003, Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma., Br. J. Cancer
    Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta
    Tsukamoto et al., 1987, Effect of calcium channel blockers and trifluoperazine on rat liver regeneration., Eur. J. Pharmacol.
  • DEOXYURIDINE MONOPHOSPHATE   TYMS

    Interaction Score: 8.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6434741 17139284 17016423 10592235


    Sources:
    DTC

  • THYMIDINE MONOPHOSPHATE   TYMS

    Interaction Score: 6.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6434741 17139284 17016423


    Sources:
    DTC

  • RALTITREXED   TYMS

    Interaction Score: 3.58

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name raltitrexed, ZD-1694,Tomudex

    PMIDs:
    10430100 10496350 10592235 10598555 10482907 18773878 10499608 11752352 10047461 17203168 16456808 15353299


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • CARBOGEN   TYMS

    Interaction Score: 3.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12915890


    Sources:
    NCI

  • DOXIFLURIDINE   TYMS

    Interaction Score: 3.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2972339


    Sources:
    NCI

  • PEMETREXED   TYMS

    Interaction Score: 2.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Alimta
    Novel drug target Established target
    Trial Name -

    PMIDs:
    21367480 23645741 23060591 26502926 11531245 12571811 11524555 11252887 12023793 15795320 11752352 11763166 11848474 14596699 11742712


    Sources:
    ClearityFoundationBiomarkers TdgClinicalTrial TEND CIViC

  • ENILURACIL   TYMS

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10692560


    Sources:
    NCI

  • ARFOLITIXORIN   TYMS

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Modufolin
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • OSI-7904   TYMS

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name OSI-7904L
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • FLOXURIDINE   TYMS

    Interaction Score: 1.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name CPX-1
    Mechanism of Interaction Thymidylate synthase inhibitor

    PMIDs:
    10553409 10482907 10891536 10697524 10697523


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND

  • TEGAFUR   TYMS

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name UFT
    Novel drug target Established target
    Trial Name S-1, TS1

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • CAPECITABINE   TYMS

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Thymidylate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    16926630 15709193 15866500 11752352 15132128 15134221


    Sources:
    ClearityFoundationBiomarkers ClearityFoundationClinicalTrial ChemblInteractions

  • PHENTOLAMINE   TYMS

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2866100


    Sources:
    NCI

  • 9-AMINOCAMPTOTHECIN   TYMS

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10803925


    Sources:
    NCI

  • HYDROXYCHLOROQUINE   TYMS

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18322994


    Sources:
    PharmGKB

  • PLATINUM   TYMS

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25677447


    Sources:
    PharmGKB

  • TOPOTECAN   TYMS

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10803925


    Sources:
    NCI

  • FLUOROURACIL   TYMS

    Interaction Score: 0.22

    Interaction Types & Directionality:
    other/unknown
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Thymidylate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    24450514 16563096 16609021 16596248 16538493 16719540 11752352 15353299 20628391 25544046


    Sources:
    DTC ClearityFoundationClinicalTrial ChemblInteractions CIViC

  • IRINOTECAN   TYMS

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21273624 16456808 20628391


    Sources:
    CIViC PharmGKB

  • SULFASALAZINE   TYMS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18322994


    Sources:
    PharmGKB

  • RESERPINE   TYMS

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2866100


    Sources:
    NCI

  • AZATHIOPRINE   TYMS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26332308


    Sources:
    PharmGKB

  • LEUCOVORIN   TYMS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Fusilev
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • ASPARAGINASE   TYMS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VERAPAMIL   TYMS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3436366


    Sources:
    NCI

  • AZACITIDINE   TYMS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29205204


    Sources:
    PharmGKB

  • INDOMETHACIN   TYMS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2707640


    Sources:
    NCI

  • HYDROCORTISONE   TYMS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2707640


    Sources:
    NCI

  • DEXAMETHASONE   TYMS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3398844 2707640


    Sources:
    NCI PharmGKB

  • DAUNORUBICIN   TYMS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2967076


    Sources:
    NCI PharmGKB

  • VINCRISTINE   TYMS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2804079


    Sources:
    NCI

  • TAMOXIFEN   TYMS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9615734


    Sources:
    NCI

  • PREDNISONE   TYMS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHOTREXATE   TYMS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    23652803 24284432


    Sources:
    CIViC

  • CYTARABINE   TYMS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ETOPOSIDE   TYMS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   TYMS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3337743


    Sources:
    NCI

  • Ensembl: ENSG00000176890

    • Version: 101_38

    Alternate Names:
    TYMS Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • HopkinsGroom: P04818

    • Version: 11-September-2012

    Alternate Names:
    ENSG00000176890 Ensembl Gene Id
    7298 Entrez Gene Id
    P04818 Uniprot Accession

    Gene Info:
    Interpro Short Name Thymidylate_synthase
    Human Readable Name DRUGGABLE GENOME
    Interpro Name Thymidylate synthase

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000176890

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000176890 Ensembl Gene Id
    TYMS Display Id
    THYMIDYLATE SYNTHASE (EC 2.1.1.45) (TS) (TSASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04818] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P04818

    • Version: January-2014

    Alternate Names:
    TYMS Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:2.1.1.45

    Publications:

  • TEND: P04818

    • Version: 01-August-2011

    Alternate Names:
    TYMS Gene Symbol
    7298 Entrez Gene Id
    ENSG00000176890 Ensembl Gene Id

    Gene Info:
    Target Main Class Enzymes
    Target Subclass 2.1.1.45

    Publications:

  • PharmGKB: TYMS

    • Version: 18-August-2020

    Alternate Names:
    PA359 PharmGKB ID

    Gene Info:

    Publications:
    James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol
    Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
    Visani G et al., 2018, MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine., Pharmacogenomics J

  • CIViC: TYMS

    • Version: 14-September-2020

    Alternate Names:
    7298 Entrez Gene ID
    5971 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Kasai et al., 2013, Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma., Anticancer Res.
    Shimizu et al., 2012, Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer., Anticancer Res.
    Chen et al., 2011, Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed., Lung Cancer

  • NCI: TYMS

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Tsukamoto et al., 1989, Effect of glucocorticoid on liver regeneration after partial hepatectomy in the rat., Gut
    Voeller et al., 2000, Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs., Cancer Chemother. Pharmacol.
    Barbour et al., 1988, Glucocorticoid regulation of the genes encoding thymidine kinase, thymidylate synthase, and ornithine decarboxylase in P1798 cells., Mol. Endocrinol.

  • DTC: TYMS

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Pelà M et al., 2014, Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth., J Med Chem
    Goldstein S et al., 1984, Interaction of N4-hydroxy-2'-deoxycytidylic acid with thymidylate synthetase., J Med Chem

  • HingoraniCasas: ENSG00000176890

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000176890 Gene Symbol
    TYMS Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: TS

    • Version: chembl_23

    Alternate Names:
    TS GENE_SYMBOL
    TYMS GENE_SYMBOL
    Thymidylate synthase UNIPROT

    Gene Info:

    Publications:

  • Tempus: TYMS

    • Version: 11-November-2018

    Alternate Names:
    TYMS Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Thymidylate synthase

    • Version: 2020.06.01

    Alternate Names:
    TYMS TTD Gene Abbreviation
    T98397 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: TYMS

    • Version: 01-February-2022

    Alternate Names:
    Thymidylate synthase Gene Name
    P04818 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • ClearityFoundationClinicalTrial: TYMS

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationBiomarkers: TYMS

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21